Drug class in one race
Mutant IDH1 drugs for Acute Myeloid Leukemia
2 tracked Mutant IDH1 drugs in the Acute Myeloid Leukemia race. The class explanation lives on the Mutant IDH1 page; the full indication pipeline across every mechanism is on the Acute Myeloid Leukemia page.
1 approved / phase 41 Phase 3
Head-to-head evidence: Ivosidenib vs Olutasidenib